For patients with DTC who have undergone total or near-total thyroidectomy and subsequent RAI therapy, a low-iodine diet is followed and levothyroxine sodium tablets are withdrawn for 3 weeks prior to RAI treatment, with the patient's serum TSH level exceeding 30 µIU/mL.
Conditions
Interventions
Observation group:None
Sponsors
Shanxi Bethune Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with DTC who have undergone total or near-total thyroidectomy and subsequent RAI therapy, following a low-iodine diet and withdrawal of levothyroxine sodium tablets for 3 weeks prior to RAI treatment, with serum TSH level >30 µIU/mL; 2. Completion of routine thyroid function tests and relevant imaging examinations before RAI therapy; 3. No significant contraindications to 131I treatment; 4. No prior history of other malignancies, immunological diseases, or organ transplantation; 5. Life expectancy of at least 1 year; 6. Study subjects are informed of the study content, participate voluntarily, and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients who decline treatment after diagnosis; 2. Patients with major organ damage that prevents completion of the treatment regimen; 3. Patients with serum TSH level still <30 µIU/mL after a low-iodine diet and withdrawal of levothyroxine sodium tablets for 3 weeks; 4. Patients who died from other causes during follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| For patients without metastasis, assess whether remnant ablation is successful; for patients with metastasis, determine whether radioiodine-refractory DTC has developed.; | — |
Countries
China
Contacts
Public ContactLiu Ye
Shanxi Bethune Hospital
Outcome results
None listed